15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
September 26, 2022 09:00 ET | Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies from the G-MAB Library
September 15, 2022 15:34 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication of peer-reviewed data detailing the discovery and preclinical...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients (7 of 7) with an Inadequate Response to Subcutaneous Injections
September 15, 2022 09:00 ET | Sorrento Therapeutics, Inc.
Sorrento has now completed its first Phase 1b human proof of concept study where the first 7 out of 7 patients with an inadequate initial response on etanercept subcutaneous injections achieved...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14
September 08, 2022 09:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D., Chairman, President and Chief Executive Officer, and...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)
August 30, 2022 23:21 ET | Sorrento Therapeutics, Inc.
SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
August 23, 2022 09:00 ET | Sorrento Therapeutics, Inc.
Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR in advanced NSCLC patients who are resistant to first-line EGFR...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Announces China National Medical Products Administration (NMPA) IND Clearance of STI-1558, An Oral Mpro Inhibitor for Phase I Trial In COVID-19 Patients
August 19, 2022 09:00 ET | Sorrento Therapeutics, Inc.
STI-1558, an oral SARS-CoV-2 main protease (Mpro) inhibitor, which can block viral replication, is specifically designed as a standalone treatment of COVID-19 without ritonavir as a booster.Single...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido® across certain designated territories including Middle East and North Africa
August 17, 2022 09:00 ET | Sorrento Therapeutics, Inc.
PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Scilex Holding Company, a Sorrento Company, Announces Expanding Coverage to 30 Million Lives And Will Continue To Work To Access An Additional 20 Million Lives With One Of The Largest National Pharmacy Benefit Managers (PBMs) For ZTlido® (lidocaine topical system) 1.8%
August 16, 2022 09:00 ET | Sorrento Therapeutics, Inc.
30 million lives now covered by one of the largest national PBMsContinue to work with this PBM to access an additional 20 million livesThe team continues to work with the national PBM’s and health...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
August 03, 2022 09:00 ET | Sorrento Therapeutics, Inc.
Single ascending dose (SAD) Phase 1 Study completed in Australia with a maximum dose of 2,000 mg.Pharmacokinetics (PK) were dose proportional and PK modeling and preclinical data support a 600 mg...